We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.98%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$49.2B
AUM Growth
+$3.24B
(+7.1%)
Cap. Flow
+$512M
Cap. Flow
% of AUM
1.04%
Top 10 Holdings %
Top 10 Hldgs %
15.87%
Holding
2,920
New
16
Increased
1,206
Reduced
1,586
Closed
85
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$23.3M |
| 2 |
Becton Dickinson
BDX
|
+$18.4M |
| 3 |
Amazon
AMZN
|
+$16.1M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$15.4M |
| 5 |
Johnson & Johnson
JNJ
|
+$14.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCR
CR Bard Inc.
BCR
|
+$48.1M |
| 2 |
LVLT
Level 3 Communications Inc
LVLT
|
+$27.7M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
+$10.7M |
| 4 |
PRXL
Parexel International Corp
PRXL
|
+$10.3M |
| 5 |
CELG
Celgene Corp
CELG
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.9% |
| 2 | Technology | 16.24% |
| 3 | Healthcare | 13.01% |
| 4 | Industrials | 10.83% |
| 5 | Consumer Discretionary | 9.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Costamare
CMRE
$1.87B
| $242K | ﹤0.01% |
41,870
-4,470
| -10% | -$26.5K |
|
|
CALA
2552
DELISTED
Calithera Biosciences, Inc
CALA
| $241K | ﹤0.01% |
1,442
-287
| -17% | -$73.5K |
|
2553
Southern First Bancshares
SFST
$579M
| $240K | ﹤0.01% |
5,822
-1,054
| -15% | -$41.9K |
|
|
CHFN
2554
DELISTED
Charter Financial Corp
CHFN
| $240K | ﹤0.01% |
13,697
-2,599
| -16% | -$47.9K |
|
|
ZIXI
2555
DELISTED
Zix Corporation
ZIXI
| $239K | ﹤0.01% |
54,641
-9,594
| -15% | -$45.2K |
|
|
BFIN
2556
DELISTED
BankFinancial
BFIN
| $238K | ﹤0.01% |
15,497
-2,990
| -16% | -$47.8K |
|
|
INSY
2557
DELISTED
Insys Therapeutics, Inc.
INSY
| $238K | ﹤0.01% |
24,705
-7,140
| -22% | -$46.7K |
|
|
RDFN
2558
DELISTED
Redfin
RDFN
| $237K | ﹤0.01% |
+7,558
| New | +$184K |
|
|
BHVN
2559
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $237K | ﹤0.01% |
8,773
-1,787
| -17% | -$49.2K |
|
2560
Addus HomeCare
ADUS
$2.18B
| $236K | ﹤0.01% |
6,791
-1,480
| -18% | -$50.3K |
|
|
AGEN
2561
Agenus
AGEN
$329M
| $235K | ﹤0.01% |
3,667
-759
| -17% | -$57.9K |
|
2562
Commercial Vehicle Group
CVGI
$147M
| $235K | ﹤0.01% |
22,002
-5,404
| -20% | -$51.9K |
|
2563
United States Lime & Minerals
USLM
$3.24B
| $235K | ﹤0.01% |
15,260
-1,500
| -9% | -$25.9K |
|
|
VRAY
2564
DELISTED
ViewRay, Inc.
VRAY
| $235K | ﹤0.01% |
25,419
-5,228
| -17% | -$41.8K |
|
|
VSI
2565
DELISTED
Vitamin Shoppe Inc.
VSI
| $235K | ﹤0.01% |
53,327
+8,100
| +18% | +$35.6K |
|
2566
RCI Hospitality Holdings
RICK
$197M
| $234K | ﹤0.01% |
8,353
| – | – |
|
|
CNBKA
2567
DELISTED
Century Bancorp Inc/Mass
CNBKA
| $234K | ﹤0.01% |
2,986
-600
| -17% | -$50.5K |
|
|
PTVCB
2568
DELISTED
Protective Insurance Corporation Class B Common Stock
PTVCB
| $234K | ﹤0.01% |
9,766
-2,259
| -19% | -$52.6K |
|
2569
FreightCar America
RAIL
$261M
| $233K | ﹤0.01% |
13,654
-2,160
| -14% | -$37.3K |
|
2570
Twin Disc
TWIN
$329M
| $232K | ﹤0.01% |
8,748
-1,387
| -14% | -$34K |
|
2571
Goldgroup Mining Inc.
GORO
$168M
| $231K | ﹤0.01% |
52,583
-9,334
| -15% | -$36.5K |
|
2572
Weyco Group
WEYS
$377M
| $231K | ﹤0.01% |
7,768
-1,230
| -14% | -$34.6K |
|
|
CRCM
2573
DELISTED
CARE.COM, INC.
CRCM
| $231K | ﹤0.01% |
12,808
-2,623
| -17% | -$45.9K |
|
2574
First Internet Bancorp
INBK
$229M
| $230K | ﹤0.01% |
6,029
-615
| -9% | -$23K |
|
|
PVLA
2575
Palvella Therapeutics
PVLA
$2.15B
| $230K | ﹤0.01% |
380
-88
| -19% | -$40.9K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2017 Portfolio in Review
As of Q4 2017, RhumbLine Advisers held 2,920 positions worth $49.2B, up 7.1% from $46B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Trading was light in Q4 2017: portfolio turnover was 3.5%. RhumbLine Advisers opened 16 new positions and exited 85, leaving the 2,920-position portfolio largely intact.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 17% a quarter earlier, followed by Technology and Healthcare.
- RhumbLine Advisers's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 187,382 shares worth $9.83M.
- RhumbLine Advisers added most to Microsoft in Q4 2017, an estimated $23.3M increase.
- RhumbLine Advisers's biggest Q4 2017 reduction was Celgene Corp, cutting an estimated $10.2M.
- RhumbLine Advisers fully exited CR Bard Inc. in Q4 2017, selling an estimated $48.1M.
- RhumbLine Advisers's ten largest holdings make up 16% of its $49.2B portfolio in Q4 2017.
- RhumbLine Advisers opened 16 new positions and closed 85 in Q4 2017.
- RhumbLine Advisers's portfolio value rose 7.1% quarter-over-quarter to $49.2B.
Based on RhumbLine Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.